In today’s briefing:
- Yunkang Group IPO – Futile to Try and Gauge Its Post-COVID Performance
Yunkang Group IPO – Futile to Try and Gauge Its Post-COVID Performance
- Yunkang Group (2325 HK) is looking to raise US$139m in its Hong Kong IPO.
- Yunkang Group has grown its on-site diagnostics centers and has grand plans to add new centers with the IPO proceeds.
- However, its business performance had been largely impacted by COVID, where COVID-related tests amounted to 83.6% of total tests performed in FY21, while contributing 58.1% to total revenue.
Before it’s here, it’s on Smartkarma
